ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
Journal of Clinical Oncology
◽
10.1200/jco.2015.33.15_suppl.8612
◽
2015
◽
Vol 33
(15_suppl)
◽
pp. 8612-8612
◽
Cited By ~ 1
Author(s):
Jeffrey A. Zonder
◽
Noopur S. Raje
◽
Emma Catherine Scott
◽
Craig C. Hofmeister
◽
Nikoletta Lendvai
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Related Documents
Cited By
References
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology
◽
10.1016/s1470-2045(19)30788-0
◽
2020
◽
Vol 21
(2)
◽
pp. 207-221
◽
Cited By ~ 72
Author(s):
Sagar Lonial
◽
Hans C Lee
◽
Ashraf Badros
◽
Suzanne Trudel
◽
Ajay K Nooka
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
International Journal of Hematology
◽
10.1007/s12185-019-02757-0
◽
2019
◽
Vol 111
(1)
◽
pp. 65-74
◽
Cited By ~ 3
Author(s):
Kohmei Kubo
◽
Mitsuo Hori
◽
Kensuke Ohta
◽
Hiroshi Handa
◽
Kiyohiko Hatake
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Newly Diagnosed
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Journal of Hematology & Oncology
◽
10.1186/1756-8722-6-41
◽
2013
◽
Vol 6
(1)
◽
Cited By ~ 24
Author(s):
Jian Hou
◽
Xin Du
◽
Jie Jin
◽
Zhen Cai
◽
Fangping Chen
◽
...
Keyword(s):
Multiple Myeloma
◽
Low Dose
◽
Chinese Patients
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
13 / An Open-label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
10.26226/morressier.5b3b802db1b87b000eceda02
◽
2018
◽
Author(s):
Fonseca Rafael
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Community Oncology
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/j.clml.2017.07.148
◽
2017
◽
Vol 17
◽
pp. S333-S334
◽
Cited By ~ 1
Author(s):
Meletios Dimopoulos
◽
Sebastian Grosicki
◽
Wiesław Jędrzejczak
◽
Hareth Nahi
◽
Astrid Gruber
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Newly Diagnosed
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/j.clml.2018.07.131
◽
2018
◽
Vol 18
◽
pp. S240-S241
Author(s):
Rafael Fonseca
◽
Melissa Alsina
◽
Jesus Berdeja
◽
Stephen B. Heitner
◽
Christopher Morris
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Community Oncology
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Case Medical Research
◽
10.31525/ct1-nct04287855
◽
2020
◽
Author(s):
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/s2152-2650(21)02333-8
◽
2021
◽
Vol 21
◽
pp. S152
Author(s):
Philippe Moreau
◽
Sosana Delimpasi
◽
Eirini Katodritou
◽
Angelo Belotti
◽
Jason Melear
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
◽
Select Trial
Download Full-text
Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718028323.793480222
◽
2013
◽
Author(s):
Richard Riedel
Keyword(s):
Soft Tissue
◽
Soft Tissue Sarcoma
◽
Phase 2
◽
Efficacy And Safety
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
◽
Metastatic Soft Tissue Sarcoma
◽
Previously Treated
Download Full-text
Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
Annals of Oncology
◽
10.1093/annonc/mdw379.04
◽
2016
◽
Vol 27
◽
pp. vi380
◽
Cited By ~ 10
Author(s):
J. Chesney
◽
F. Collichio
◽
R.H.I. Andtbacka
◽
I. Puzanov
◽
J. Glaspy
◽
...
Keyword(s):
Stage Iiib
◽
Phase 2
◽
Talimogene Laherparepvec
◽
Open Label
◽
Safety And Efficacy
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close